Hansa Medical will present the drug candidate IdeS’s potential as a novel treatment for desensitization prior to kidney transplantation, at the poster session on July 27 at the 2014 World Transplant Congress in San Francisco, USA. The World Transplant Congress gathers international experts on transplantation, attracts prominent keynote speakers as well as pharmaceutical and biotechnology companies committed to the improvement of treatment of transplantation patients. For more information about the World Transplant Congress, please visit: www.wtc2014.org The poster presentation will emphasize IdeS’ antibody deactivating effect and safety, demonstrated in a recently concluded Phase I study in healthy volunteers as well as in sera from sensitized patients pre-kidney transplantation. More on IdeS Hansa Medicals’ drug candidate IdeS is developed as a fast, safe and expedient method to deactivate IgG-antibodies in sensitized patients prior to kidney transplantation. For sensitized patients, IgG-antibodies pose the primary obstacle for a transplant, forcing patients into years of treatment in dialysis. A successful Phase I-study was finalized in January 2014 and a Phase II study is planned for 2014 in sensitized patients awaiting kidney transplantation. For further information, please contact: Hansa Medical AB Emanuel Björne, CEO Hansa Medical AB (publ) Mobile: 46 707 17 54 77 E-mail: emanuel.bjorne@hansamedical.com www.hansamedical.com Hansa Medical pursues clinical development and commercialization of innovative pharmaceuticals and diagnostic methods for the benefit of patients with serious and rare inflammatory diseases. The portfolio includes a marketed diagnostic product, a drug candidate in clinical development, and a preclinical research project. Major shareholders are Bo Håkansson via Farstorps Gård AB, and Nexttobe AB. Hansa Medical is listed on NASDAQ OMX First North (HMED) and Remium Nordic AB is the company’s Certified Adviser.
Hansa Medical to present IdeS at the 2014 World Transplant
Top 10 Most Recent News Articles
EZaccessMD Data Breach: Class Action Lawsuit Looms
Data breaches are the bogeyman no one wants lurking in the shadows, and when it’s your personal info at stake, folks rightfully squirm. This recent fiasco at EZaccessMD is one of those unsettling incidents. The word on the street isn't pretty: sensitive medical data has slipped through the cracks, leaving Edelson Lechtzin LLP, a heavyweight in class action maneuvers, to...
Continue Reading
PASCAL's Holiday Gift Edit: Timeless Watches Shine
Fresh Sparkle for the Holidays Well, here we are again, staring down the barrel of another holiday season. And what do you know, PASCAL is out with its 2026 Holiday Gift Edit, like clockwork. This is the kind of stuff they’re good at—capturing a moment, slapping some color on it, and calling it a game-changer. Launching on November 14, this edit nods to their Timeless...
Continue Reading
Shenzhen's Vision Unveiled: APEC 2026 Promo Debut
Shenzhen's Spotlight Moment at APEC 2026 When Shenzhen announced its promotional video for the 2026 APEC Economic Leaders' Meeting, it wasn't just about standard tourism glitz. This was a show of force, a bold step onto the main stage of global politics and economics. The video's launch wasn’t merely an audio-visual delight—it staked a claim in shaping the future...
Continue Reading
Novo's Research Unlocks New Insights into Food Noise
Unpacking the Science Behind Food Noise When folks think about losing weight, most picture shedding pounds and fitting into those elusive smaller jeans. But get this—there’s a curveball called ‘food noise’ that’s making waves in obesity treatment. Novo Nordisk’s semaglutide injections are shaking things up, cutting down on those persistent thoughts about food....
Continue Reading
YSTUDIO's Pens: A Nod to the Power of Writing
Slow Down, Write On: A New Era for Stationery In a world where sentiments zip around with a swipe, here we find YSTUDIO tapping into something analog and profound. Their latest offerings—a 'Brand Day Gift Box' and the 'Inner Universe' pen series—are more than just high-end stationery. They’re an invitation to reconnect with the written word, a gesture to slow our...
Continue Reading
Fluence Energy Faces Leadership Departures Amid Legal Woes
Fluence Energy's Rocky Road Continues It's chaos once again in the halls of Fluence Energy (NASDAQ:FLNC). The ship seems to drift further from solid ground as their CEO and CFO candidly decided to jump ship, shaking investor confidence even more vigorously. The market's reaction was swift and brutal: a nasty 9% share drop, leaving investors with more than just a headache....
Continue Reading
Servier's Data on Tovorafenib Shows Promise in pLGG
New Light on a Critical Challenge Talk about a fight in the dark. Pediatric low-grade glioma (pLGG) is a menace that families dread, an uphill battle with odds that feel relentless. Enter Servier and its four-year updated data on OJEMDA® (tovorafenib), a beacon of hope for kids battling these tricky brain tumors. Results, presented at the SNO meeting, are fresh off the...
Continue Reading
Lilly's Obesity Breakthroughs: A Step Beyond the Scale
Pushing the Boundaries of Obesity Treatment Alright, let's cut through the noise and get to what really matters here. Eli Lilly is taking on obesity treatment like it's Clash of the Titans at this year's ObesityWeek 2026 in Washington, D.C. Forget just dropping pounds—Lilly wants to reshape how we think about obesity entirely. They're not just leaning into the scale,...
Continue Reading
AppLovin Legal Woes: A Deep Dive into Investor Claims
AppLovin Faces Legal Heat and Market Scrutiny Bitter truth has a way of crashing like a wave, and AppLovin (NASDAQ: APP) is feeling the brunt of it. Now knee-deep in a securities class action, the firm’s been accused of selling fairy tales about its AI capabilities, leaving investors clutching at substantial losses. If you’ve been banking on their promises between...
Continue Reading
WHO and RCSI Bahrain Join Forces on Health Initiatives
Forging a Healthier Pathway In a world where healthcare challenges rise faster than my blood pressure during a stock market crash, the World Health Organization (WHO) and the Royal College of Surgeons in Ireland (RCSI) – Medical University of Bahrain have inked a deal to tackle these issues head-on. The memorandum of understanding (MoU) signed on November 15, 2026,...
Continue ReadingTop 5 Most Recently Viewed Articles
Century Communities Celebrates New Home Community Launch
Exciting Grand Opening for Willow Glenn Community Century Communities, Inc. (NYSE: CCS), a prominent national homebuilder, is thrilled to announce the upcoming Grand Opening for Willow Glenn, a remarkable new residential community featuring spacious, modern two-story homes. Situated with breathtaking views of Mt. Rainier, this community is designed to elevate the living...
Continue Reading
Universal Health Services Welcomes Darren Lehrich as New VP
Universal Health Services Announces New Addition to Leadership Universal Health Services, Inc. (NYSE: UHS), a key player in the healthcare sector, has recently welcomed Darren Lehrich to its leadership team as Vice President of Investor Relations. In his new capacity, Lehrich will report directly to CFO Steve Filton, aiming to enhance investor engagement in this critical...
Continue Reading
Provident Financial Services Achieves Impressive Q3 Earnings Results
Recent Earnings Update Provident Financial Services, Inc. (NYSE: PFS) has recently shared its financial results for its third quarter, showcasing a remarkable net earnings figure of $46.4 million, equivalent to $0.36 per share. These encouraging results were shared by CEO Tony Labozzetta during a call with investors. He highlighted the successful integration of the...
Continue Reading
EnviroGold Global Strengthens Board with New Executive Appointment
EnviroGold Global Welcomes Jackie Przybylowski to Board EnviroGold Global Limited (CSE: NVRO | OTCQB: ESGLF | FSE: YGK) is thrilled to announce that Jackie Przybylowski, a distinguished executive in the mining and capital markets sector, has joined its Board of Directors. This pivotal appointment takes effect as the company progresses the rollout of its innovative NVRO...
Continue Reading
Syensqo Reports Strong Q4 and Full Year 2024 Performance
Syensqo's Remarkable Fourth Quarter and Full Year 2024 Performance Syensqo recently announced its highlights for the fourth quarter and full year of 2024, showcasing impressive growth in a challenging market landscape. This performance reflects the company's resilience and strategic vision. Quarter Four Achievements During Q4 of 2024, Syensqo achieved net sales of €1.6...
Continue Reading